33 related articles for article (PubMed ID: 11091204)
1. BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors.
Rusakiewicz S; Madrigal A; Travers P; Dodi AI
Cancer Immunol Immunother; 2009 Sep; 58(9):1449-57. PubMed ID: 19360407
[TBL] [Abstract][Full Text] [Related]
2. Recurrent lymphoid and myeloid relapses due to treatment cessations reveal natural history of Ph-positive B-ALL and pose a diagnostic challenge.
Hu S; Jabbour EJ; Hu CY; Tang G; Wang W; Medeiros LJ; Bueso-Ramos C
Am J Hematol; 2024 Apr; 99(4):721-726. PubMed ID: 38240333
[No Abstract] [Full Text] [Related]
3. NK Cells in Myeloproliferative Neoplasms (MPN).
Naismith E; Steichen J; Sopper S; Wolf D
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503210
[TBL] [Abstract][Full Text] [Related]
4. Ontogeny of human B1 cells.
Kageyama Y; Katayama N
Int J Hematol; 2020 May; 111(5):628-633. PubMed ID: 31721035
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.
Carlsten M; Järås M
Front Immunol; 2019; 10():2357. PubMed ID: 31681270
[TBL] [Abstract][Full Text] [Related]
6. NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib.
Sopper S; Mustjoki S; Gjertsen BT; Giles F; Hochhaus A; Janssen JJWM; Porkka K; Wolf D
Leukemia; 2017 Oct; 31(10):2264-2267. PubMed ID: 28744011
[No Abstract] [Full Text] [Related]
7. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling.
Chen J; Schmitt A; Chen B; Rojewski M; Rübeler V; Fei F; Yu Y; Yu X; Ringhoffer M; von Harsdorf S; Greiner J; Götzz M; Guillaume P; Döhner H; Bunjes D; Schmitt M
J Cell Mol Med; 2008 Oct; 12(5B):2107-18. PubMed ID: 18194453
[TBL] [Abstract][Full Text] [Related]
8. [Fluorescent in-situ hybridization technique (FISH) in the diagnosis of Philadelphia translocation in chronic myeloid leukemia].
Martinet D; Mühlematter D; Jotterand Bellomo M
Schweiz Med Wochenschr; 1996 May; 126(20):855-63. PubMed ID: 8685681
[TBL] [Abstract][Full Text] [Related]
9. Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia.
Cho EK; Heo DS; Seol JG; Seo EJ; Chi HS; Kim ES; Lee YY; Kim BK; Kim NK
Br J Haematol; 2000 Oct; 111(1):216-22. PubMed ID: 11091204
[TBL] [Abstract][Full Text] [Related]
10. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
[TBL] [Abstract][Full Text] [Related]
11. Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia.
Jonas D; Lübbert M; Kawasaki ES; Henke M; Bross KJ; Mertelsmann R; Herrmann F
Blood; 1992 Feb; 79(4):1017-23. PubMed ID: 1371078
[TBL] [Abstract][Full Text] [Related]
12. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
Silla LM; Pincus SM; Locker JD; Glover J; Elder EM; Donnenberg AD; Nardi NB; Bryant J; Ball ED; Whiteside TL
Br J Haematol; 1996 May; 93(2):375-85. PubMed ID: 8639431
[TBL] [Abstract][Full Text] [Related]
13. [Progress in laboratory medicine in chronic myeloid leukemia].
Miura A
Rinsho Byori; 1998 Dec; 46(12):1226-31. PubMed ID: 9916508
[TBL] [Abstract][Full Text] [Related]
14. Lineage involvement in chronic myeloid leukaemia: comparison between MBCR/ABL and mBCR/ABL cases.
Primo D; Sanchez ML; Espinosa AB; Tabernero MD; Rasillo A; Sayagués JM; Gonzalez M; Hernandez JM; Orfao A
Br J Haematol; 2006 Mar; 132(6):736-9. PubMed ID: 16487173
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
